Inhibrx Price/Sales
What is the Price/Sales of Inhibrx?
The Price/Sales of Inhibrx, Inc. is 691.46
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on NASDAQ compared to Inhibrx
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Companies with price/sales similar to Inhibrx
- Insilco has Price/Sales of 672.80
- Uranium Participation has Price/Sales of 673.57
- Kadestone Capital has Price/Sales of 679.35
- Nuveen Municipal Credit Opportunities Fund has Price/Sales of 682.87
- Great Boulder Resources has Price/Sales of 687.08
- Global Atomic has Price/Sales of 690.39
- Inhibrx has Price/Sales of 691.46
- Thin Film Electronics ASA has Price/Sales of 694.91
- BioPharmX has Price/Sales of 695.03
- Petro Matad has Price/Sales of 698.32
- Chesser Resources has Price/Sales of 703.97
- Prospect Park Capital has Price/Sales of 709.23
- Shonghoya Intl Inc has Price/Sales of 712.65